Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
EMERALD, NCT02269917 / 2014-003052-31: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Completed
3
1149
Europe, Canada, US
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Janssen R&D Ireland
Human Immunodeficiency Virus Type 1
02/17
10/20
AMBER, NCT02431247 / 2015-000754-38: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Completed
3
725
Europe, Canada, US, RoW
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo
Janssen Sciences Ireland UC
Immunodeficiency Virus Type 1, Human
03/17
09/20
DIAMOND, NCT03227861: A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

Completed
3
109
US
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
Janssen Scientific Affairs, LLC
HIV-1
01/19
09/19
2018-003481-13: An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease -The Late Presenter Treatment Optimisation Study (LAPTOP)-

Not yet recruiting
3
440
Europe
Biktarvy, Symtuza, [J05AR], [J05AR22], Film-coated tablet, Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences Inc, Janssen Pharmaceutica NV, Gilead Sciences, Inc.,
Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus), A virus that damages patient's immune system causing the patient difficulty to fight off infections and diseases., Diseases [C] - Virus Diseases [C02]
 
 
BIC-T&T, NCT04653194 / 2019-003208-11: Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Completed
3
36
Europe
Biktarvy, Symtuza
Chelsea and Westminster NHS Foundation Trust, Imperial College London, Gilead Sciences
Human Immunodeficiency Virus
07/23
07/23
NCT03696160: The Late Presenter Treatment Optimisation Study

Active, not recruiting
3
447
Europe
Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals
HIV/AIDS
06/24
06/24

Download Options